ATS (ATS) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
27 Apr, 2026Company overview and business model
Industry leader in automated manufacturing and assembly systems, serving life sciences, consumer products, food & beverage, energy, and transportation sectors.
Employs over 7,000 people across 65 manufacturing facilities and 85 offices globally.
Focuses on custom automation, standard products, digital solutions, and recurring service revenues.
Pursues a value creation strategy of Build, Grow, and Expand, leveraging disciplined acquisitions and innovation.
Selective in market focus, favoring regulated industries where quality and reliability are critical.
Financial performance and metrics
Financial statements prepared in accordance with IFRS and may not be directly comparable to US GAAP.
As of April 24, 2026, qualifying public equity was $3,429,220,738.
98,114,232 common shares outstanding as of April 24, 2026.
Common shares traded on TSX and NYSE, with closing prices of $45.17 (TSX) and US$33.04 (NYSE) on April 24, 2026.
Use of proceeds and capital allocation
Net proceeds from securities offerings will be used as specified in each prospectus supplement; proceeds from secondary offerings go to selling securityholders.
Strategic capital allocation framework aims to drive long-term sustainable shareholder value.
Latest events from ATS
- C$3.0B adjusted revenue, strong M&A, and disciplined growth in automation markets.ATS
Investor presentation29 May 2026 - Revenue and earnings rose in fiscal 2026, with restructuring driving margin expansion.ATS
Q4 202628 May 2026 - Record financial results, all resolutions passed, and strategic focus on regulated markets.ATS
AGM 202419 May 2026 - C$2.9B adjusted revenues, 13.8% EBITDA margin, and robust M&A fuel global automation growth.ATS
Investor presentation19 Apr 2026 - Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q3 revenue up 16.7%, net income surges, and strong backlog supports future growth.ATS
Q3 20264 Feb 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026 - Tripled revenue, tech innovation, and services expansion drive growth in life sciences and EV.ATS
Stifel 2024 Cross Sector Insight Conference31 Jan 2026